STIMULAN gives surgeons the freedom to choose the antibiotics that support their infection treatment strategy
Artoss to benefit from Biocomposites established, global distribution network
RENOVITE ® nanoclay is a novel therapeutic delivery platform for precision regenerative medicine
Investment will help fund pre-market approval for use in spine, trauma and orthopaedics
Biocomposites, CEO, Michael Harris will join Renovos Biologics Board of Directors
Innovation is at the very heart of what we do, resulting in over 100 grants and registrations.
Access case studies, clinical and pre-clinical papers for musculoskeletal infection, trauma and spine to see how we are innovating across a wide range of clinical applications to help surgeons and their patients.
Musculoskeletal infections, including infected non-unions, osteomyelitis and periprosthetic joint infections, are one of the biggest healthcare challenges of the 21st century.
As the rapid growth of antibiotic-resistant strains and biofilms continues to outpace the development of new antibiotics and antibiotic strategies, care delivery is becoming increasingly challenging and complicated.
Bone and joint trauma, such as fractures and dislocations, are common and vary in severity from single fractures to multiple, life-threatening musculoskeletal injuries.
The most clinically challenging of these for the surgeon, and those that have the most socioeconomic burden, are open fractures. These often involve damage to the surrounding soft tissue, resulting in complications such as tissue and deep bone infection or long-term non-union.
The popularity of spine surgery differs around the world. The number of procedures performed in the USA is double the number performed in Western Europe, Canada and Australia combined, and five times the number in the UK.
In the USA, the number of spinal fusion procedures increased by 64% between 2002 and 2014, from approximately 268,000 to 414,000. The average cost per procedure has increased from $15,868 to $28,954 over the same period and was more than $12 billion in total in 2014.
At Biocomposites, we are pioneering calcium compound devices to regenerate and repair bone and soft tissue. With over 30 years’ experience of manipulating the surface chemistry and crystalline properties of calcium compounds, we engineer and manufacture products at the forefront of calcium technology.